Evidence map›Paper›PMID 41766205›Full record

Trial reportHuman vaccines & immunotherapeutics2026

Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.

Zourab Bebia, Ilse Dieussaert, Lisa Jose, Anu Kantele, Hanna Välimaa, Guy Middleton, Hemir David Escobar Pirela, Osvaldo Reyes, Marta García Sánchez, Paulino Vigil-De Gracia and 4 more

Abstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zourab BebiaGSK, Rockville, MD, USA.
Ilse DieussaertGSK, Rixensart, Belgium.
Lisa JoseSouth African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Anu KanteleMeilahti Vaccine Research Center MeVac, Department of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-0004-1000
Hanna VälimaaMeilahti Vaccine Research Center MeVac, Department of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-2187-2399
Guy MiddletonSEC Clinical Research, Dothan, AL, USA.
Hemir David Escobar PirelaHospital Universitario de Torrejón, Madrid, Spain.
Osvaldo ReyesCentro de Vacunación Internacional (CEVAXIN), Red Nacional de Investigadores de Panamá (SNI), Panama City, Panama.ORCID 0000-0002-5351-0309
Marta García SánchezObstetrics and Gynaecology Department, Hospital Quirónsalud Málaga, Malaga, Spain.ORCID 0000-0001-7292-178X
Paulino Vigil-De GraciaCAENSA Clinical Trials, National Network of Researchers of Panama, Panama City, Panama.ORCID 0000-0002-1494-3654
Nancy HuaGSK, Rockville, MD, USA.
Martha KiraboGSK, Rockville, MD, USA.
Patricia LeseGSK, Rockville, MD, USA.
Joon Hyung KimGSK, Rockville, MD, USA.ORCID 0000-0002-6014-3543

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) causes respiratory illness among infants; maternal vaccination confers passive protection through placental antibody transfer. This phase 3, randomized, placebo-controlled trial evaluated safety, reactogenicity, and immunogenicity of RSV prefusion protein F3 maternal vaccine (RSVPreF3-Mat), administered at 24

Indexed as

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAdolescentAdultAntibodies, NeutralizingAntibodies, ViralFemaleHumansImmunity, Maternally-AcquiredInfantInfant, NewbornPregnancyPregnancy Complications, InfectiousPregnancy, High-RiskPremature BirthRespiratory Syncytial Virus, HumanAntibodies, NeutralizingAntibodies, ViralRespiratory Syncytial Virus VaccinesBronchiolitishumoral immunitymaternal immunizationneonatal carepassive immunizationplacental transferpregnancypreterm birthRSVvaccines

Identifiers

PMID41766205
PMCPMC12959198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.